Angel News
Angel News

Back to Homepage

29th April 2022

Science Angel Syndicate backs MitoRx Therapeutics

MitoRx Therapeutics secures investment from Science Angel Syndicate to develop its first-in-class therapeutics that target dysfunctional sulfide-signalling in mitochondria to halt the progress of degenerative diseases.

Science Angel Syndicate (SAS) was launched in September 2021 to supportinvestments into frontier scientific discoveries that impact society on a global scale. Leveraging their unique due diligence capabilities they have supported SAS investors to make an investment into MitoRx Therapeutics. 

...

Register / Login now to read full story

In order to read the full story we need you to be registered with us, please click the links below to login or register.

Login / Register

Add a comment:

Name:

Email:

Comment:

Enter the characters in the image shown:



Back to Homepage